Inspire licenses Faes' bilastine

Faes (IBEX:FAE) granted ISPH an exclusive license in the U.S. and Canada to develop and commercialize oral bilastine to treat or prevent rhinitis, as well as an exclusive license to the ocular formulation in various markets worldwide. FAE will receive $7 million up front and is eligible for $82 million in milestones, plus a 14-16% royalty on U.S. and Canadian sales of oral bilastine. FAE has completed two European Phase III trials of the oral formulation to treat seasonal allergic rhinitis. ...